Last reviewed · How we verify
Lower Dose Sodium Bicarbonate
Lower dose sodium bicarbonate raises blood and urine pH to reduce acid load and slow progression of chronic kidney disease.
Lower dose sodium bicarbonate raises blood and urine pH to reduce acid load and slow progression of chronic kidney disease. Used for Chronic kidney disease with metabolic acidosis.
At a glance
| Generic name | Lower Dose Sodium Bicarbonate |
|---|---|
| Sponsor | Jennifer Gassman, PhD |
| Drug class | Alkalizing agent |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
Sodium bicarbonate is an alkalizing agent that buffers systemic acidosis, a known contributor to kidney disease progression. By reducing metabolic acidosis through oral supplementation at lower doses than traditional use, it may slow glomerular filtration rate decline and preserve renal function. This mechanism is particularly relevant in chronic kidney disease where acidosis accelerates tubular damage and fibrosis.
Approved indications
- Chronic kidney disease with metabolic acidosis
Common side effects
- Hypernatremia
- Gastrointestinal disturbance
- Alkalosis
Key clinical trials
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy
- The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress (NA)
- Effectiveness of Sodium Hyaluronate In Relieving Nasal Symptoms Of Children With Seasonal Allergic Rhinitis (NA)
- The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR) (PHASE3)
- Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Aluminium Phosphide Poisoning (PHASE4)
- Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain (PHASE1)
- Acid-Base Compensation in Chronic Kidney Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |